A Study on the Role of Thrombophilic Genetic Disorders as a Risk Factor for Thrombotic Complications in Patients with Myeloproliferative Disorders-Reference-Cited by-同舟云学术

A Study on the Role of Thrombophilic Genetic Disorders as a Risk Factor for Thrombotic Complications in Patients with Myeloproliferative Disorders

Published:2019-07-01 Issue:1 Volume:12 Page:19-26
ISSN:1313-9053
Container-title:Journal of Biomedical and Clinical Research
language:en
Short-container-title:

Author:

Todorieva-Todorova Doroteya K.¹,Kovacheva Katya S.²,Tzvetkov Nikolay T.¹,Trifonov Stefan V.³,Stavreva Galya Ts.⁴,Rashev Tihomir R.⁵,Todorov Alexander A.³,Ivanov Petar D.⁶

Affiliation:

1. Hematology Division , Medical University - Pleven , Bulgaria

2. Medical Genetics Section , Medical University - Pleven , Bulgaria

3. Department of Anatomy, Histology, Cytology and Biology , Medical University - Pleven , Bulgaria

4. Department of Pharmacology and Toxicology , Medical University - Pleven , Bulgaria

5. Division of Molecular Biology , University Scientific Research Laboratory, Medical University - Pleven , Bulgaria

6. Biochemistry Section , Medical University - Pleven , Bulgaria

Abstract

Summary Myeloproliferative neoplasms (MPN) are haematological diseases, characterized by clonal hematopoiesis. Hemostasis abnormalities are among the most critical and frequent complications, affecting the quality of life and a possible reason for death. Thrombotic complications are common and multifactorial. Our aim was to study some genetic thrombophilia factors – Factor V Leiden (FVL), G20210A mutation in prothrombin gene (PR G20210A) and PLA2 allele polymorphism of glycoprotein IIIa gene (GPIIIa gene), and their frequency and association with thrombotic risk in both Philadelphia-positive and Philadelphia-negative MPN – chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary and secondary myelofibrosis (MF). In our patient population, PLA2 allele polymorphism of GPIIIa gene proved to be the most common and significantly associated with thrombotic complications – 26.85% of our patients were carriers, and 24.14% of them reported thrombotic complications.

Publisher

Walter de Gruyter GmbH

Subject

General Medicine

Link

https://www.sciendo.com/pdf/10.2478/jbcr-2019-0003

Reference36 articles.

1. 1. Gercheva-Kyuchukova L. [Chronic myeloproliferative neoplasms]. 1st ed. Pleven: Peychinski. 2016. Bulgarian.

2. 2. Lutzkanova E, Marinova I, Pavlova D, Todorov V, Tzvetkov N. [Hematology]. In: Internal diseases part II – medical student book. 1st ed. Pleven: Medical University; 2012, p. 320-34. Bulgarian.

3. 3. Aftab A, Naghmi A, Hassan K. Portal vein thrombosis in a case of chronic myeloid leukemia – a rare association. JIMDC.2013;2(4):87-9.

4. 4. Jain A, Gupta N, Singh T, Agarwal S. A study of haemostatic parameters in patients of chronic myeloid leukaemia. J Clin Diagn Res. 2016;10(7):0C19-0C23.

5. 5. Sora F, Iurlo A, Sica S, Latagliata R, Annunziata M, Galimberti S, et al. Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome. Br J Haematol. 2018;181(2):267-70.